News — BOSTON, April 29, 2025 /PRÂ鶹´«Ã½wire/ -- Granata Bio ("Granata") today announced the acquisition of Oviva Therapeutics, Inc. ("Oviva"), a pioneering women's health biotech company focused on advancing treatments that address female physiology, with an emphasis on ovarian aging.
Oviva's lead candidate, OVI-586, is a first-in-class therapeutic designed to enhance women's health span— the period of life spent in optimal health— by extending ovarian function. Since the ovaries are the first organ to decline with age, preserving the ovarian reserve presents a novel approach to addressing key women's health challenges. OVI-586 holds potential applications across menopause, contraception, and in vitro fertilization (IVF), offering new possibilities for patients seeking advanced reproductive and endocrine health solutions.
"This is a big day for women's health. Cambrian partnered with Drs. Daisy Robinton, David Pepin, and Pat Donahue to found Oviva and develop the first truly novel mechanism in women's health in the last 50 years. We're thrilled about this acquisition and looking forward to seeing Oviva's OVI-586 progress to the next stage of development under Granata's leadership. This transaction reflects the importance of Cambrian's objective: identify amazing scientific discoveries and turn those discoveries into great businesses," said James Peyer, Founder and CEO of Cambrian BioPharma, Inc.
"At Granata Bio, our mission is to identify and develop innovative solutions for fertility patients. The acquisition of Oviva Therapeutics marks a significant milestone in our efforts to bring forward new therapies for those with limited treatment options. In IVF stimulation, OVI-586 offers a biologically grounded approach to improving ovarian response— even in patients with diminished ovarian reserve. We're excited to continue advancing OVI-586 and explore its potential in assisted reproductive technology (ART) and beyond," said Evan Sussman, Co-Founder and CEO of Granata Bio.
About Oviva Therapeutics
Oviva Therapeutics, Inc. is leading a movement to improve women's experience of aging through biomedical research, development and advocacy. Oviva addresses the vast unmet need in women's health by expanding funding, research, and clinical development, and is currently developing first-in-class therapeutics to improve ovarian function and consequently extend female healthspan.
About Granata Bio
Granata Bio is a U.S.-based biopharmaceutical company dedicated to advancing innovation in women's health and infertility. Founded in 2018, the company's pipeline includes a range of fertility therapies, with collaborations spanning multiple drug classes to address unmet needs in reproductive medicine.
RSS